Eli Lilly pauses its obesity awareness campaign in India following regulatory scrutiny, according to reports citing a communication from the company to India’s drug regulator. Business Standard reports that in a 16-page letter dated April 10 to the Drugs Controller General of India, Lilly says it has halted the campaign “out of an abundance of regulatory caution” after receiving a March advisory. The reports indicate the company is responding to concerns raised by regulators about the campaign’s compliance and any promotional or informational boundaries. While details of the campaign and the specific points in the advisory are not fully set out in the available summaries, the company’s explanation centers on caution and compliance. The Economic Times article discusses the decision to stop the campaign but does not add additional details in the provided text. Overall, the information across sources points to a pause in Lilly’s obesity awareness efforts in India, driven by an advisory issued by regulators in March and subsequent scrutiny that prompted the company to seek or respond to regulatory guidance.